| Psoriasis vulgaris
Tazorac vs Wynzora
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Tazorac vs Wynzora with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWynzora has a higher rate of injection site reactions vs Tazorac based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wynzora but not Tazorac, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tazorac
Wynzora
At A Glance
Topical
Daily
Retinoid
Topical
Daily
Vitamin D3 analog + corticosteroid
Indications
- Psoriasis vulgaris
- Acne Vulgaris
- Psoriasis vulgaris
Dosing
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Psoriasis vulgaris Apply to affected areas once daily for up to 8 weeks; do not use more than 100 g per week; discontinue when control is achieved.
Contraindications
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
—
Adverse Reactions
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Most common (>=1%) Upper respiratory infection, headache, application site irritation
Postmarketing Atrophy, striae, telangiectasias, itching, dryness, hypopigmentation, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure
Pharmacology
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
WYNZORA Cream combines calcipotriene, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; the exact mechanisms of their actions in plaque psoriasis are unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Tazorac.
Wynzora
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Tazorac.
Wynzora
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
No coverage data available for Tazorac.
Wynzora
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tazorac.
No savings programs available for Wynzora.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TazoracView full Tazorac profile
WynzoraView full Wynzora profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.